Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver: insights from models of obesity and type 2 diabetes11Abbreviations: PPAR, peroxisome proliferator-activated receptor; 15d-PGJ2, 15-deoxy-Δ12,14-prostaglandin J2; NEFA, non-esterified fatty acid; T2DM, type 2 (non-insulin-dependent) diabetes mellitus; LPS, lipopolysaccharide; NSAIDs, nonsteroidal anti-inflammatory drugs; IL, interleukin; TNF α, tumor necrosis factor-α; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; and TZD, thiazolidinedione.
- 1 January 2002
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 63 (1) , 1-10
- https://doi.org/10.1016/s0006-2952(01)00817-6
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Diabetic KKAy mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinedionesPublished by Elsevier ,2001
- PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancerTrends in Pharmacological Sciences, 2000
- Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by PioglitazoneBiochemical and Biophysical Research Communications, 2000
- Peroxisome Proliferator–Activated Receptor-γ Ligands Inhibit Nitric Oxide Synthesis in Vascular Smooth Muscle CellsHypertension, 2000
- Body Composition and Hepatic Steatosis As Precursors for Fibrotic Liver DiseaseHepatology, 1999
- Mitochondrial Proteins That Regulate Apoptosis and Necrosis Are Induced in Mouse Fatty LiverHepatology, 1999
- Troglitazone Exhibits Immunomodulatory Activity on the Cytokine Production of Activated Human LymphocytesHormone and Metabolic Research, 1999
- TroglitazoneDrugs, 1999
- PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoterFEBS Letters, 1998
- mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.Genes & Development, 1994